ArticleFrontiers in medicine2026
Case Report: Vogt-Koyanagi-Harada-like uveitis associated with combined dabrafenib/trametinib and cadonilimab therapy for cutaneous melanoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several BRAF kinase inhibitors (BRAFis), MEK kinase inhibitors (MEKis), and immune checkpoint inhibitors have been linked with the occurrence of Vogt-Koyanagi-Harada (VKH)-like uveitis. However, there are no reported cases of VKH-like uveitis induced by the combined administration of dabrafenib, trametinib, and cadonilimab to date. Case presentation: This paper presents a case of VKH-like uveitis in a patient with inguinal melanoma following combined treatment with dabrafenib, trametinib, and cadonilimab. Four months after the initiation of this combined therapy, the patient developed severe bilateral acute panuveitis complicated by exudative retinal detachment, and a diagnosis of bilateral VKH-like uveitis was considered. The patient's ocular condition of both eyes improved after the discontinuation of dabrafenib and trametinib, along with the administration of topical and systemic glucocorticoid therapy. At the time of drug discontinuation, the patient's metastatic liver lesions remained stable, and no melanoma progression was observed during the 1-year follow-up. Conclusion: This report demonstrates that VKH-like uveitis may occur in patients receiving combined treatment with dabrafenib, trametinib, and cadonilimab, and emphasizes the importance of monitoring for ocular complications in patients undergoing long-term treatment with this regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.